Timothy Eugene Sullivan Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Timothy Eugene Sullivan is Chief Financial Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 132,299 shares of APLS, which is worth approximately $3.99 Million. The most recent transaction as insider was on Jan 21, 2025, when has been sold 45,929 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 132K

67.1% 3M change

38.28% 12M change

Total Value Held $3.99 Million

Timothy Eugene Sullivan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 21 2025	BUY Grant, award, or other acquisition	-	45,929 Added 25.77%	132,299 Common Stock
Jan 17 2025	SELL Open market or private sale	$51,830 $29.96 p/Share	1,730 Reduced 1.96%	86,370 Common Stock
Jan 13 2025	SELL Open market or private sale	$62,279 $28.7 p/Share	2,170 Reduced 2.4%	88,100 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	$159,782 $14.4 p/Share	11,096 Added 10.95%	90,270 Common Stock
Apr 18 2024	SELL Bona fide gift	-	14,164 Reduced 15.17%	79,174 Common Stock
Apr 01 2024	SELL Open market or private sale	$234,640 $58.66 p/Share	4,000 Reduced 4.11%	93,338 Common Stock
Apr 01 2024	BUY Exercise of conversion of derivative security	$40,120 $10.03 p/Share	4,000 Added 3.95%	97,338 Common Stock
Mar 01 2024	SELL Open market or private sale	$380,460 $63.41 p/Share	6,000 Reduced 6.04%	93,338 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$60,179 $10.03 p/Share	6,000 Added 5.7%	99,338 Common Stock
Feb 12 2024	SELL Open market or private sale	$96,978 $67.77 p/Share	1,431 Reduced 1.51%	93,338 Common Stock
Jan 29 2024	SELL Open market or private sale	$58,110 $64.14 p/Share	906 Reduced 0.95%	94,769 Common Stock
Jan 22 2024	SELL Open market or private sale	$230,815 $65.0 p/Share	3,551 Reduced 3.58%	95,675 Common Stock
Jan 16 2024	SELL Open market or private sale	$149,320 $66.81 p/Share	2,235 Reduced 2.2%	99,226 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	23,748 Added 18.97%	101,461 Common Stock
Nov 30 2023	SELL Open market or private sale	$775,292 $54.76 p/Share	14,158 Reduced 15.41%	77,713 Common Stock
Nov 30 2023	BUY Exercise of conversion of derivative security	$142,004 $10.03 p/Share	14,158 Added 13.35%	91,871 Common Stock
Jul 03 2023	SELL Open market or private sale	$612,211 $90.31 p/Share	6,779 Reduced 8.02%	77,713 Common Stock
Jul 03 2023	BUY Exercise of conversion of derivative security	$67,993 $10.03 p/Share	6,779 Added 7.43%	84,492 Common Stock
Jun 05 2023	SELL Open market or private sale	$6,220,797 $89.15 p/Share	69,779 Reduced 47.31%	77,713 Common Stock
Jun 05 2023	BUY Exercise of conversion of derivative security	$699,883 $10.03 p/Share	69,779 Added 32.12%	147,492 Common Stock
May 03 2023	SELL Bona fide gift	-	20,000 Reduced 20.47%	77,713 Common Stock
Apr 19 2023	SELL Bona fide gift	-	36,232 Reduced 27.05%	97,713 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$56,979 $58.5 p/Share	974 Reduced 0.72%	133,945 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	11,683 Added 7.97%	134,919 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$49,929 $51.21 p/Share	975 Reduced 0.78%	123,236 Common Stock

TES

Timothy Eugene Sullivan

Chief Financial Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account